Within the new analysis, data from the CHAMPION, GUIDE-HF and LAPTOP-HF4 trials were combined to assess the mortality and heart failure hospitalizations of 1,350 HFrEF patients. Among the three randomized trials, more than 650 patients were subjected to hemodynamic monitoring and 684 received the control. Heart failure hospitalizations were analyzed over a 12-month follow-up period and all-cause mortality was evaluated across 24 months.
The meta-analysis validated that hemodynamic monitoring can slow the progression of heart failure in HFrEF patients by significantly decreasing heart failure-related hospitalizations and improving survival.
"These new findings are encouraging news for physicians and the millions of people living with a progressive disease for which there is no cure," said Philip B. Adamson, M.D., chief medical officer of Abbott's heart failure business. "Heart Failure is a growing health crisis that demands innovative solutions and now we have a clinically-proven life-extending option for this population."
The CardioMEMS HF System is approved for use in people living with New York Heart Association (NYHA) Class II or III heart failure who either have been hospitalized for heart failure in the previous year or for patients who undergo a blood test showing elevated levels of biomarkers known as natriuretic peptides, which indicate worsening heart failure. The hemodynamic data are used by physicians for heart failure management with the goal of controlling pulmonary artery pressures and reducing heart failure hospitalizations. The CardioMEMS sensor first received approval from the U.S. Food and Drug Administration (FDA) in 2014.
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries.
Back to HCB News
